{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:05:37Z","timestamp":1764072337681,"version":"3.45.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,10]]},"abstract":"<jats:sec>\n                    <jats:title>Rational:<\/jats:title>\n                    <jats:p>The Philadelphia chromosome (Ph) is seen in most patients with chronic myeloid leukemia and some patients with acute lymphoblastic leukemia. However, Ph-positive acute myeloid leukemia (Ph\u2005+\u2005AML) is a rare entity with a poor prognosis and a short median survival period. To date, there have been few clinical reports on this disease. And the treatment regimen of this disease has not been uniformly determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We report a case of a Ph\u2005+\u2005AML. A 32-year-old male who was admitted to our hospital with weakness for 2 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Philadelphia chromosome-positive acute myeloid leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient achieved complete remission by the administration of a tyrosine kinase inhibitor, combined with low-intensity chemotherapy and a B-cell lymphoma 2 inhibitor. Then, allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his sister was successfully performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient has been in a continuous remission state for 6 months after transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>We reported a rare Ph\u2005+\u2005AML case, successfully treated with allo-HSCT. This case provided strong support for treating Ph\u2005+\u2005AML with allo-HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000038110","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T14:02:37Z","timestamp":1715349757000},"page":"e38110","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Philadelphia chromosome-positive acute myeloid leukemia successfully treated by allogeneic hematopoietic stem cell transplantation: A case report and review of the literature"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5636-9034","authenticated-orcid":false,"given":"Zhichen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China"},{"name":"First School of Clinical Medicine, Ningxia Medical University, Yinchuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaofeng","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China"},{"name":"First School of Clinical Medicine, Ningxia Medical University, Yinchuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianli","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuexia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2078-7689","authenticated-orcid":false,"given":"Yaozhu","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People\u2019s Liberation Army, Lanzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251125","first-page":"1866","article-title":"Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.","volume":"9","author":"McLaughlin","year":"1989","journal-title":"Mol Cell Biol"},{"key":"R2-20251125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10428194.2012.701739","article-title":"Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.","volume":"54","author":"Konoplev","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R3-20251125","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","article-title":"Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.","volume":"127","author":"Soupir","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R4-20251125","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R5-20251125","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00277-016-2721-z","article-title":"BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.","volume":"95","author":"Neuendorff","year":"2016","journal-title":"Ann Hematol"},{"key":"R6-20251125","doi-asserted-by":"crossref","first-page":"107002","DOI":"10.1016\/j.leukres.2022.107002","article-title":"Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia.","volume":"124","author":"Zhou","year":"2023","journal-title":"Leuk Res"},{"key":"R7-20251125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.hemonc.2014.09.002","article-title":"Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome.","volume":"8","author":"Reboursiere","year":"2015","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R8-20251125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"R9-20251125","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.leukres.2009.03.017","article-title":"Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and BCR-ABL transcripts.","volume":"33","author":"Kondo","year":"2009","journal-title":"Leuk Res"},{"key":"R10-20251125","doi-asserted-by":"crossref","first-page":"126758","DOI":"10.1016\/j.bmcl.2019.126758","article-title":"Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants.","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"R11-20251125","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.bbmt.2018.04.020","article-title":"Impact of an additional chromosome on the clinical outcomes of hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia in adults.","volume":"24","author":"Min","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-20251125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.24928","article-title":"Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: a survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).","volume":"93","author":"Lazarevic","year":"2018","journal-title":"Am J Hematol"},{"key":"R13-20251125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-014-0059-3","article-title":"Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).","volume":"7","author":"Lai","year":"2014","journal-title":"J Hematol Oncol"},{"key":"R14-20251125","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"R15-20251125","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study.","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R16-20251125","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","article-title":"An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.","volume":"56","author":"Jimenez Jimenez","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R17-20251125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000334109","article-title":"Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia.","volume":"127","author":"Sun","year":"2012","journal-title":"Acta Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:01:20Z","timestamp":1764072080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":17,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038110","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}